Adc Therapeutics SA [ADCT] stock is trading at $3.33, up 3.74%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ADCT shares have gain 7.42% over the last week, with a monthly amount glided 13.27%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on March 28, 2024, and set its price target to $11. On August 10, 2023, upgrade upgraded it’s rating to Neutral. BofA Securities downgraded its rating to a Underperform and decreased its price target to $2 on April 24, 2023. CapitalOne initiated its recommendation with a Overweight and recommended $12 as its price target on December 06, 2022. BofA Securities downgraded its rating to Neutral for this stock on November 09, 2022, and downed its price target to $7. In a note dated September 21, 2022, JP Morgan initiated an Overweight rating and provided a target price of $5 on this stock.
Adc Therapeutics SA [ADCT] stock has fluctuated between $0.36 and $6.04 over the past year. Currently, Wall Street analysts expect the stock to reach $9.33 within the next 12 months. Adc Therapeutics SA [NYSE: ADCT] shares were valued at $3.33 at the most recent close of the market. An investor can expect a potential return of 180.18% based on the average ADCT price forecast.
Analyzing the ADCT fundamentals
Adc Therapeutics SA [NYSE:ADCT] reported sales of 66.75M for the trailing twelve months, which represents a drop of -9.71%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -2.1%, Pretax Profit Margin comes in at -2.54%, and Net Profit Margin reading is -3.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is 1.63 and Total Capital is -0.45. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.87.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.22 points at the first support level, and at 3.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.42, and for the 2nd resistance point, it is at 3.50.
Ratios To Look Out For
For context, Adc Therapeutics SA’s Current Ratio is 6.17. Further, the Quick Ratio stands at 5.90, while the Cash Ratio is 5.21. Considering the valuation of this stock, the price to sales ratio is 4.82.
Transactions by insiders
Recent insider trading involved Redmile Group, LLC, 10% Owner, that happened on Jul 01 ’24 when 0.4 million shares were purchased. 10% Owner, Redmile Group, LLC completed a deal on Jul 01 ’24 to buy 0.4 million shares. Meanwhile, Director Azelby Robert sold 6995.0 shares on Jun 17 ’24.
